I.I. Gorpynchenko, V.L. Karbovskyy, I.A. Shevchuk, O.V. Kurkin, T.Ye. Makovska

Evaluation of «Prostecs» efficacy in treating chronic abacterial prostatitis

The article sets forth the results of a clinical investigation into the efficacy and safety of using medical product «Prostecs» to treat patients with chronic abacterial prostatitis. «Prostecs» is shown to be an effective medication for treating chronic prostatitis, since after its 10-day use there was seen a considerable reduction in the palpatory signs of inflammation (density, edema and pain), as well as in the number of leukocytes in the prostatic fluid. The therapy with medical product «Prostecs» improves the quality of live for chronic prostatitis patients, as is evidenced by the decrease in the number of the disease clinical manifestations, evaluated with the aid of chronic prostatitis symptoms index (questionnaire NIH-CPSI, 1999).

The core laboratory indicators of the urine and blood were found to remain within the age norm limits and to have significant dynamics. During the therapy no patient, included in the study, revealed no complains, side effects, complications or intolerance effects, this enabling «Prostecs» to be recommended for use as an effective and safe medication to treat patients with chronic prostatitis. In its efficacy, medical product «Prostecs» (LLC «Pharmaceutical plant «Biofarma», Bila Tserkva, Ukraine) is therapeutically equivalent to reference drug «Prostatilene» (PJSC «Lekhim-Kharkiv», Kharkiv), since no statistically significant difference between the study and control groups was revealed.